Compare CHMI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | SERA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 90.6M |
| IPO Year | 2013 | 2021 |
| Metric | CHMI | SERA |
|---|---|---|
| Price | $2.51 | $3.56 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 253.0K | 42.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | $95,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | $31.73 | $400.00 |
| P/E Ratio | $135.57 | ★ N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $2.17 | $1.37 |
| 52 Week High | $3.68 | $9.13 |
| Indicator | CHMI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 64.67 |
| Support Level | $2.43 | $2.91 |
| Resistance Level | $2.60 | $3.14 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 78.75 | 96.71 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.